Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Brand profile · Biotechnology Research
Singapore-based DotBio operates in Biotechnology Research. Ownership is privately held; it publishes at dotbiopharma.com. It holds one address on record, all in Singapore. The record counts 23 people. Tagged oncology and DotBody technology. One Singapore registration (UEN) is a confirmed match. Its latest round on record is Seed, US$5.6M. It is listed alongside six similar brands, mostly in Biotechnology Research.
UEN201715654D
| DOTBIO PTE. LTD. | UEN 201715654D |
|---|---|
| Confirmed matches | 1 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
DotBio is focused on the development of novel immuno-oncology drugs based on humanized domain antibodies, its proprietary DotBody technology. DotBodies are domain therapeutic antibodies which are multi-specific, humanized and highly-stable. The company was founded by Professor Pär Nordlund and Dr. Ignacio Asial, who designed and conceptualized the DotBody technology based on their expertise in protein and antibody engineering at Singapore’s Nanyang Technological University. For more information visit www.dotbiopharma.com
| Countries | 1 |
|---|---|
| Primary country | SG |
All codes: SG
| Rounds | 4 |
|---|---|
| Axis | 2018 to 2026 |
| Seed · 7 Sep 2023 | US$ 5.6M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Hiring, headcount and registry-change signals, streamed to members.
Registry-filed capital and financial indicators, standardised by TheGrid.
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
One Singapore entity on ACRA. DOTBIO PTE. LTD. (UEN 201715654D), high confidence.
The record holds 23 counted staff profiles at January 2026, above the self-reported 2–10 band.
One address on record, Singapore only. Primary: 1 Research Link, Singapore, 11.
Four rounds. Latest 7 September 2023: Seed, US$5,600,000, investors Prox Ventures and Gaorong Capital.
One tag on the brand's own list, among them Oncology and DotBody technology.
11 profiles list DotBio as a peer — 84th percentile in Biotechnology Research. It lists ten peers of its own. Acoerela and Avecris list it back.